Ross\Johnson & Associates’s Halozyme HALO Stock Holding History

Ross\Johnson & Associates’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$269	–	272
2025 Q4	$269	Buy	+4	New	+$269	0.01%	218

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ross\Johnson & Associates's HALO Position: Q1 2026 in Review

Ross\Johnson & Associates sold out of Halozyme (HALO) in Q1 2026, closing a stake of 4 shares — an estimated $269 sold.

Ross\Johnson & Associates first reported a position in HALO in Q4 2025 and held it in 1 quarter. The position peaked at $269 in Q4 2025. 637 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

Ross\Johnson & Associates reported no remaining Halozyme position as of Q1 2026 after selling out during the quarter.
Ross\Johnson & Associates sold 4 Halozyme shares in Q1 2026, an estimated $269.
Ross\Johnson & Associates first reported a position in Halozyme in Q4 2025 and held it in 1 quarter.
Ross\Johnson & Associates's Halozyme position peaked at $269 in Q4 2025.
637 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.